A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme

Inclusion Criteria: Age: 18 years to 70 years; Newly diagnosed Glioblastoma in the supratentorial cerebralhemisphere; Gross total resection or large resection of >70% in imaging studies; EasternCooperative Oncology Group performance status of 0-2; Adequate bone marrow, liver and renalfunction; Ability of subject to understand character and individual consequences of theclinical trial Written informed consent; anticipating survival ≥7 months.

Exclusion Criteria: Refusal to participate the study; Current diagnosis or history of malignancies within the 3-year period preceding enrollment; Recurrent or multiple malignant gliomas, includinggliomatosis cerebri, or metastatic extracalvarial or subtentorial lesions; Knownhypersensitivity or contraindication to temozolomide; Pregnant or lactating females;Malignant tumor other than brain tumor; Contraindicated for MRI examination; Unable tocomply with the follow-up studies of this trial; Uncontrolled psychotic disorders orepilepsy.